# Adaptive Trials Capability Analysis - rctbayespower Package
**Date:** November 24, 2025
**Status:** Comprehensive Gap Analysis

## Executive Summary

This report analyzes the `rctbayespower` package's current capabilities for simulating adaptive clinical trials against industry-standard use cases and research questions. Based on web search findings and package analysis, we identify critical gaps and provide recommendations for full adaptive trial support.

## Part 1: Industry Use Cases and Research Questions (2024-2025)

### 1.1 Common Adaptive Design Types in Practice

Based on FDA guidance and recent publications, the following adaptive designs are most commonly used:

1. **Group Sequential Designs** (Most Common)
   - Used in 53% of adaptive trials (oncology focus)
   - Early stopping for efficacy or futility
   - O'Brien-Fleming or Pocock boundaries
   - Can reduce sample size by ~15% under alternative hypothesis

2. **Sample Size Re-estimation** (SSR)
   - Promising zone designs
   - Conditional power-based adjustments
   - Blinded or unblinded re-estimation
   - GRAPHITE trial (NCT03657160) as exemplar

3. **Adaptive Randomization**
   - Response-adaptive randomization (RAR)
   - Outcome-adaptive allocation
   - Bayesian adaptive randomization

4. **Dose Finding Designs**
   - BDMA (Bayesian Dynamic Model-Based Adaptive) design
   - Continual reassessment method (CRM)
   - BOIN designs
   - Project Optimus requirements for oncology

5. **Platform Trials**
   - Multiple arms entering/leaving
   - Common control arm
   - Perpetual trials

6. **Basket/Umbrella Trials**
   - Basket: One treatment, multiple diseases (biomarker-driven)
   - Umbrella: Multiple treatments, one disease
   - Master protocols

7. **Seamless Phase II/III Designs**
   - Dose selection followed by confirmation
   - Combined analysis across phases

### 1.2 Key Research Questions Addressed by Adaptive Trials

1. **Efficacy Questions**
   - "Can we stop early if treatment is clearly effective?"
   - "What is the optimal dose that balances efficacy and safety?"
   - "Which of multiple treatments performs best?"

2. **Futility Questions**
   - "Should we stop if success is unlikely?"
   - "What is the probability of success given current data?"
   - "Is the treatment effect clinically meaningful?"

3. **Resource Optimization**
   - "How can we minimize expected sample size?"
   - "What is the most efficient allocation ratio?"
   - "Can we reduce trial duration while maintaining power?"

4. **Personalized Medicine**
   - "Which biomarker subgroups benefit most?"
   - "How to adapt treatment based on patient characteristics?"
   - "Can we identify responder populations early?"

5. **Rare Disease Challenges**
   - "How to conduct trials with very small populations?"
   - "Can we borrow information across similar diseases?"
   - "How to maximize information from limited patients?"

### 1.3 Critical Decision Rules and Metrics

Modern adaptive trials require evaluation of:

1. **Posterior Probabilities**
   - P(treatment effect > threshold | data)
   - P(treatment in ROPE | data)
   - P(superiority | data)

2. **Predictive Probabilities**
   - P(success at trial end | interim data)
   - Conditional power
   - Predictive probability of success (PPoS)

3. **Decision Thresholds**
   - Success: Often P(effect > MCID) > 0.975
   - Futility: Often P(effect < 0) > 0.5 or P(success at end) < 0.1
   - Practical equivalence: P(effect in ROPE) > 0.95

4. **Operating Characteristics**
   - Type I error control
   - Power across effect sizes
   - Expected sample size
   - Probability of early stopping

## Part 2: Current Package Capabilities

### 2.1 What the Package CAN Do

#### ‚úÖ **Implemented Features**

1. **Basic Bayesian Power Analysis**
   - Fixed sample size designs
   - ROPE-based decision making
   - Posterior probability calculations
   - Power across parameter grids

2. **Model Types**
   - ANCOVA for continuous outcomes (2 or 3 arms)
   - Flexible prior specifications
   - Design priors for integrated power

3. **Decision Framework**
   - Success/futility thresholds
   - Probability-based decisions
   - ROPE implementation

4. **Computational Infrastructure**
   - Parallel processing
   - Model caching
   - Efficient Stan/brms integration

5. **Visualization**
   - Power curves
   - Grid analyses
   - Auto-detection of plot types

#### üöß **Planned but Not Implemented (Interim Analysis)**

Per the implementation plan, the following will be added:
- Sequential analyses at specified sample sizes
- Early stopping for success/futility
- Adaptive parameter modification
- Continue simulation after stopping
- Expected sample size calculations

### 2.2 What the Package CANNOT Do (Critical Gaps)

#### ‚ùå **Missing Core Adaptive Features**

1. **No Interim Analysis Implementation**
   - Status: Detailed plan exists, not implemented
   - Impact: Cannot simulate ANY group sequential designs
   - Cannot evaluate early stopping
   - No conditional power calculations

2. **No Sample Size Re-estimation**
   - Cannot adjust sample size based on interim variance estimates
   - No promising zone implementation
   - No blinded SSR capabilities

3. **No Adaptive Randomization**
   - No response-adaptive randomization
   - No outcome-adaptive allocation
   - No play-the-winner strategies

4. **Limited Outcome Types**
   - Only continuous outcomes
   - No binary outcomes (critical for many trials)
   - No time-to-event/survival outcomes
   - No count/rate outcomes
   - No ordinal outcomes

5. **No Dose Finding Capabilities**
   - No CRM implementation
   - No BOIN designs
   - No dose-escalation schemes
   - Cannot handle dose-response modeling

6. **No Platform/Basket/Umbrella Support**
   - Cannot add/drop arms dynamically
   - No shared control arm capabilities
   - No biomarker stratification
   - No master protocol support

7. **No Multiplicity Adjustment**
   - No alpha spending functions
   - No gatekeeping procedures
   - No hierarchical testing

## Part 3: Gap Analysis for Practical Scenarios

### 3.1 Scenario Evaluation Matrix

| Scenario | Can Simulate? | Missing Components |
|----------|--------------|-------------------|
| **Basic RCT with fixed sample** | ‚úÖ Yes | None |
| **Group sequential with O'Brien-Fleming** | ‚ùå No | Interim analysis, alpha spending |
| **Futility stopping only** | ‚ùå No | Interim analysis implementation |
| **Sample size re-estimation** | ‚ùå No | SSR logic, interim analysis |
| **Response-adaptive randomization** | ‚ùå No | Adaptive allocation, interim analysis |
| **Dose escalation (3+3, CRM)** | ‚ùå No | Dose models, escalation rules |
| **Platform trial with arm dropping** | ‚ùå No | Dynamic arms, master protocol |
| **Basket trial (biomarker-driven)** | ‚ùå No | Multiple diseases, biomarker models |
| **Binary outcome with interim** | ‚ùå No | Binary models, interim analysis |
| **Time-to-event with early stopping** | ‚ùå No | Survival models, interim analysis |
| **Pediatric dose finding** | ‚ùå No | Dose models, safety constraints |
| **Rare disease with borrowing** | ‚ùå No | Historical borrowing, hierarchical models |

### 3.2 Research Questions the Package Can/Cannot Address

#### ‚úÖ **Questions It CAN Answer**

1. "What sample size do I need for 80% power?" (fixed design)
2. "How does power change with effect size?" (continuous outcomes only)
3. "What is the probability the treatment effect exceeds MCID?"
4. "How do different priors affect power?"

#### ‚ùå **Questions It CANNOT Answer**

1. "When should I stop the trial early?" (no interim analysis)
2. "What is the expected sample size with early stopping?" (no interim)
3. "How should I adapt allocation based on responses?" (no RAR)
4. "What dose should I select for Phase III?" (no dose finding)
5. "Which biomarker subgroup benefits most?" (no stratification)
6. "What is the probability of success at trial end given interim data?" (no predictive probability)
7. "How do I control Type I error with multiple looks?" (no alpha spending)
8. "What is the optimal futility boundary?" (no boundary optimization)

## Part 4: Requirements for Comprehensive Adaptive Trial Support

### 4.1 Priority 1: Core Interim Analysis (Planned)

**Status:** Implementation plan exists (16-23 hours estimated)

Required for:
- Group sequential designs (most common adaptive design)
- Early stopping decisions
- Conditional power calculations
- Expected sample size metrics

### 4.2 Priority 2: Binary and Survival Outcomes

**Status:** Not planned

Required for:
- Most oncology trials (overall response rate, progression-free survival)
- COVID-19 trials (mortality, ventilation)
- Cardiovascular trials (MACE endpoints)

Implementation needs:
- Binary data generation
- Logistic regression in brms
- Survival data generation
- Cox/parametric survival models

### 4.3 Priority 3: Sample Size Re-estimation

**Status:** Not planned

Required for:
- Variance uncertainty
- Effect size uncertainty
- Regulatory compliance (FDA guidance)

Implementation needs:
- Conditional power calculations
- Blinded variance estimation
- Sample size modification logic

### 4.4 Priority 4: Adaptive Randomization

**Status:** Partially planned (parameter modification in interim plan)

Required for:
- Ethical considerations (more patients on better treatment)
- Efficiency gains
- Patient benefit

Implementation needs:
- Response-adaptive algorithms
- Drift protection
- Randomization probability bounds

### 4.5 Priority 5: Dose Finding

**Status:** Not planned

Required for:
- Phase I trials
- Phase I/II designs
- FDA Project Optimus compliance

Implementation needs:
- Dose-response models
- Toxicity/efficacy modeling
- Escalation/de-escalation rules

## Part 5: Recommendations

### 5.1 Immediate Actions (Enable Basic Adaptive Trials)

1. **Implement the interim analysis plan** (16-23 hours)
   - This alone would enable group sequential designs
   - Covers the most common adaptive design type
   - Foundation for other adaptive features

2. **Add binary outcome support** (8-12 hours estimated)
   - Create `build_model_logistic_2arms()`
   - Binary data generation
   - Adapt compute_measures for binary outcomes

3. **Add survival outcome support** (12-16 hours estimated)
   - Create `build_model_survival_2arms()`
   - Time-to-event data generation
   - Censoring mechanisms

### 5.2 Medium-term Enhancements

4. **Sample size re-estimation** (8-12 hours)
   - Build on interim analysis infrastructure
   - Add conditional power calculations
   - Implement promising zone logic

5. **Response-adaptive randomization** (12-16 hours)
   - Extend adaptive parameter modification
   - Add allocation probability calculations
   - Implement common RAR algorithms

### 5.3 Long-term Vision

6. **Platform trial support** (20-30 hours)
   - Dynamic arm management
   - Shared control arms
   - Perpetual trial infrastructure

7. **Dose finding module** (20-30 hours)
   - CRM implementation
   - BOIN designs
   - Dose-response modeling

8. **Master protocol framework** (30-40 hours)
   - Basket trial support
   - Umbrella trial support
   - Biomarker stratification

## Part 6: Competitive Analysis

### Packages with Adaptive Trial Capabilities

1. **Commercial Software**
   - EAST (full adaptive suite)
   - nQuery (adaptive module)
   - FACTS (Bayesian adaptive)
   - SAS PROC SEQDESIGN

2. **R Packages**
   - `rpact`: Comprehensive adaptive trials
   - `gsDesign`: Group sequential
   - `adaptr`: Adaptive trials
   - `bcrm`: Bayesian CRM for dose finding

3. **Gap for rctbayespower**
   - Unique: Bayesian power with ROPE
   - Unique: S7 architecture
   - Missing: Most adaptive features competitors have

## Conclusion

The `rctbayespower` package has a solid foundation for Bayesian power analysis but **lacks most features needed for adaptive trial simulation**. The most critical gap is the absence of interim analysis functionality, which is required for ~84% of adaptive trials (group sequential designs).

### Minimum Viable Product for Adaptive Trials

To claim adaptive trial support, the package needs:
1. ‚úÖ Interim analysis implementation (planned)
2. ‚ùå Binary outcomes (not planned)
3. ‚ùå Survival outcomes (not planned)
4. ‚ùå Sample size re-estimation (not planned)

### Current Verdict

**The package is NOT ready for simulating adaptive trials relevant to most practical scenarios and research questions.** However, with the planned interim analysis implementation plus binary/survival outcomes, it would cover ~70% of common use cases.

### Recommended Path Forward

1. **Phase 1** (1 month): Implement interim analysis as planned
2. **Phase 2** (2 weeks): Add binary and survival outcomes
3. **Phase 3** (2 weeks): Add sample size re-estimation
4. **Phase 4** (1 month): Add response-adaptive randomization

This would position `rctbayespower` as a competitive Bayesian adaptive trial simulation package within 2-3 months of focused development.